Skip to main content

These Juno investors will cash out big in Celgene's $9 billion takeover

Juno's top investors will cash out stock worth hundreds of millions of dollars in the biotech company’s pending acquisition by Celgene Corp.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.